



RECEIVED

1652

\$

in x Seq

TECH CENTER 1800/2900

PATENT  
250/192

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

George P. Vlasuk, et al.

Serial No. 09/498,272

Filed: February 4, 2000

For: NEMATODE-EXTRACTED  
SERINE PROTEASE  
INHIBITORS AND  
ANTICOAGULANT PROTEINSGroup Art Unit: Not Yet  
Assigned

Examiner: Not Yet Assigned

TECH CENTER 1800/2900

5/16  
4/15  
19/2/14TRANSMITTALAssistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Transmitted herewith for filing in the above-referenced  
application are the following:

- Communication in Regard to Sequence Listing;
- Copy of Formalities Letter;
- Petition for Extension of Time;
- Copy of Sequence Listing previously submitted for  
08/809,455 and ASCII Disk;

SD-150987.1

CERTIFICATE OF MAILING  
(37 C.F.R. §1.8a)I hereby certify that this paper (along with any referred to as being attached  
or enclosed) is being deposited with the United States Postal Service on the  
date shown below with sufficient postage as First Class Mail in an envelope  
addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

Name of Person Mailing Paper

Signature of Person Mailing Paper


Patent  
250/192

- Check in the amount of \$55.00; and
- Return postcard.

No additional fee is believed due with this Communication, but if additional fees are due, please charge any such fee to our Deposit Account No. 12-2475 for the appropriate amount.

Respectfully submitted,  
LYON & LYON LLP

Date: June 7, 2005

  
Suzanne L. Biggs  
Registration No. 30,158

LYON & LYON LLP  
633 West Fifth Street, Suite 4700  
Los Angeles, CA 90071-2066

Telephone: (858) 552-8400  
Facsimile: (213) 955-0440



Patent  
216/270

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

George P. Vlasuk et al.

Serial No. 08/809,455

Filed: April 14, 1997

For: NEMATODE-EXTRACTED SERINE  
PROTEASE INHIBITORS AND  
ANTICOAGULANT PROTEIN

Group Art Unit: 1652

Examiner: Lau, K.

STATEMENT UNDER 37 C.F.R. § 1.821 (F)

Assistant Commissioner of Patents  
Washington, D.C. 20231


Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821 (e), (f) and (g), or § 1.825 (d) and (b) respectively, are the same.

Respectfully submitted,

LYON & LYON LLP

By

  
Suzanne L. Biggs  
Reg. No. 30,158

633 West Fifth Street, 47th Floor  
Los Angeles, CA 90071-2066  
(619) 552-8400

SD-91467.1

CERTIFICATE OF MAILING  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

October 30, 1998

Date of Deposit  
Paper

Amanda Halverson  
Name of Person Mailing Paper

Amanda Halverson  
Signature of Person Mailing



Patent  
216 270

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

George P. Vlasuk et al.

Serial No. 08/809,455

Filed: April 14, 1997

For: NEMATODE-EXTRACTED SERINE  
PROTEASE INHIBITORS AND  
ANTICOAGULANT PROTEIN

Group Art Unit: 1652

Examiner: Lau, K.

RESPONSE TO COMMUNICATION

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Responsive to the Communication mailed October 1, 1998,  
Applicants submit herewith the "Sequence Listing" in computer  
readable form as required under § 1.824 (a).

Specifically, the Sequence Listing is provided on ASCII  
text on the accompanying diskette and the Statement under § 1.821  
(f) is provided.

SD-91463.1

CERTIFICATE OF MAILING  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached  
or enclosed) is being deposited with the United States Postal Service on the  
date shown below with sufficient postage as First Class Mail in an envelope  
addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

October 30, 1998  
Date of Deposit

Amanda Halverson  
Name of Person Mailing Paper

Amanda Halverson  
Signature of Person Mailing Paper

Patent  
216/270


No new matter has been added to the Specification.  
Please enter the enclosed Sequence Listing into the  
Specification.

At this time, no fee is believed due in connection with this  
Response, however, please charge Deposit Account No. 12-2475 for  
any deficiencies.

Respectfully submitted,

LYON & LYON LLP

By

  
Suzanne L. Biggs  
Reg. No. 30,158

633 West Fifth Street, 47th Floor  
Los Angeles, CA 90071-2066  
(619) 552-8400

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s).



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

## Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).



For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212


For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**



**7 AU**  
VOLUME

Applicant:	V. J. S. et al
S/n:	08/809,455
Filed:	April 17, 1999
For:	Nematode - Extracted
	Serine protease inhibitors
	+ Anticancerous protein
Corvas	212/272



to SB  
4/14/00

## FORMALITIES LETTER




\*OC000000005033460\*

UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark OfficeAddress: COMMISSIONER OF PATENT AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/498,272	02/04/2000	George Phillip Vlasuk	250/192

Suzanne L Biggs  
Lyon & Lyon LLP  
633 West Fifth Street 47th Floor  
Los Angeles, CA 90071



Date Mailed: 04/06/2000

*DATA Ser Rev del: 5/6/00*

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s)
  - This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
  - A copy of the "Sequence Listing" in computer readable form has not been submitted as required under 37 CFR 1.821(e).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-1123
- For CRF Submission Help, call (703) 308-4212
- PatentIn Software Program Support
- - For Technical Assistance, call (703) 287-0200
- - To Purchase PatentIn Software, call (703) 306-2800

*A copy of this notice **MUST** be returned with the reply.*

*Begina Fields*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE





250/192  
Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	)	Group Art Unit: Not Yet
	)	Assigned
George P. Vlasuk, et al.	)	
Serial No. 09/498,272	)	Examiner: Not Yet Assigned
Filed: February 4, 2000	)	
For: NEMATODE-EXTRACTED	)	
SERINE PROTEASE	)	
INHIBITORS AND	)	
ANTICOAGULANT PROTEINS	)	

**COMMUNICATION IN REGARD TO SEQUENCE LISTING**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to § 1.821(e), Applicants note that the Sequence Listing filed October 30, 1998, in parent application Serial No. 08/809,455, filed April 14, 1997, is identical to that in the above-identified application Serial No. 09/498,272.

SD-150974.1

**CERTIFICATE OF MAILING**  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

June 7, 2000  
Date of Deposit

Amanda Halverson  
Name of Person Mailing Paper

Amanda Halverson  
Signature of Person Mailing Paper

Patent  
250/192

A paper copy of the Sequence Listing and ASCII Diskette is enclosed.


It is understood that the Patent and Trademark Office will make the necessary change in the application number and filing date for the computer readable form that will be used for the instant application.

Enclosed is a check in the amount of \$55.00 for a one-month extension of time in connection with the submission of this communication. No further fee is believed due in connection with this communication. If any fee is due, please charge Deposit Account 12-2475 appropriately.

Respectfully submitted,

LYON & LYON LLP

Dated: June 7, 2000

  
Suzanne L. Biggs  
Registration No. 30,158

LYON & LYON LLP  
633 West Fifth Street  
Suite 4700  
Los Angeles, CA 90071-2066

Telephone: (858) 552-8400  
Facsimile: (213) 955-0440